![FDA Watch: Another First as Agency Approves NGS Oncology Companion Dx for Multiple Therapies](https://www.g2intelligence.com/wp-content/uploads/2023/04/56181_G2_stock_3-1080x675.jpg)
FDA Watch: Another First as Agency Approves NGS Oncology Companion Dx for Multiple Therapies
From - Laboratory Industry Report
The FDA made a stir in May by approving a cancer drug (Keytruda (pembrolizumab) PD-1/PD-L1 inhibitor from Merck) administered on the basis of a…